AiLife International Group Limited Overview
AiLife International Group Limited is, in operating terms, still the business historically known as Ling Yui: a small Hong Kong foundation-engineering contractor that performs excavation and lateral support (ELS), pile cap and pile construction, site formation and ancillary road and drainage works, overwhelmingly for private-sector developments and usually for main contractors. With FY2026 revenue of HK$179.3 million, a loss of HK$11.4 million, 74 employees and equity of HK$45.5 million, it is a micro-cap participant in a fragmented, price-competitive and cyclical local market that has been depressed by high interest rates and weak private-residential development. The April 2026 acquisition of 70.02% by Hapbiotech — a vehicle of Shenzhen genomics and liquid-biopsy group HaploX — followed by the rebrand to "AiLife" and the appointment of HaploX's two founders as executive directors, signals a probable strategic pivot towards AI-enabled life sciences. No such transaction has yet been announced, so the equity now trades largely on change-of-control optionality rather than on construction fundamentals.
Company's own description (paraphrased from the FY2026 Annual Report)
The FY2026 Management Discussion and Analysis characterises the Group as a Hong Kong-based main contractor that principally provides foundation works — namely excavation and lateral support works, pile cap works and pile construction — plus site formation works and ancillary services such as road and drainage works, for foundation projects in the private sector. The Group reports a single operating segment: the provision of foundation engineering services. All revenue-generating operations and borrowings are denominated in Hong Kong dollars.
At IPO in 2017 the Group described itself as a subcontractor working mainly through Ming Lee Foundation for main contractors of private foundation projects, undertaking specific parts of foundation work designated by the main contractor (Prospectus, 2017; Ipsos). The shift in self-description from "subcontractor" (2017) to "main contractor" (2025–2026 reports) reflects the Group's stated objective of obtaining additional qualifications to tender directly as a main contractor; Ming Lee Engineering Company Limited holds an authorised-signatory registration in the Foundation category (senior management bio of Mr. Lo Hin Chi, FY2026 AR).
Business model and revenue model
Revenue model: ~100% project-based construction contract revenue recognised over time (HKFRS 15). There is no subscription, licensing or recurring service income. Minor "other income" lines include sale of waste material, machinery rental income, gains on equipment disposal, interest and compensation (HK$3.8M in FY2026 vs HK$0.7M in FY2025).
Product vs service mix: Effectively 100% services (construction works). Not publicly disclosed as a percentage split, but the single-segment disclosure makes the characterisation unambiguous.
Cost structure: Direct costs (subcontracting, labour, materials, machinery depreciation and fuel) represented ~92% of revenue in FY2026 (HK$165.7M of HK$179.3M). Administrative expenses were HK$26.6M. Total staff costs (incl. directors and MPF) were HK$35.6M.
Asset base: The Group owns machinery and construction equipment (e.g., excavators with hydraulic hammers and telescopic arms per aggregator description); machinery with net book value of HK$9.0M was pledged to banks and a financial institution at 31 Mar 2026 (HK$11.9M at 31 Mar 2025).
Working-capital intensity: Contract assets, retention receivables and trade receivables are large relative to revenue, which is why the expected-credit-loss (ECL) charge of HK$22.2M in FY2025 was decisive for that year's loss.
Value-chain position
In Hong Kong's construction chain (developer → main contractor → specialist/foundation contractor → sub-subcontractors/labour), Ling Yui sits at the specialist-foundation layer. It wins work either as subcontractor to the main contractor engaged by the developer or, increasingly, as foundation main contractor where the developer lets the foundation package separately. It in turn engages subcontractors and suppliers (steel, concrete, machinery rental) and bears responsibility for their performance.
Customer types and end-markets
Customers: Main contractors engaged by property developers; property developers directly for foundation packages; the FY2026 chairman's statement indicates a new project team targeting "prominent clients" and the public foundation sector as a potential growth avenue.
End-markets: Private residential and commercial property development in Hong Kong (dominant); public works (aspirational).
Concentration: The company lists as a principal risk that a significant portion of revenue comes from non-recurring contracts awarded by a few customers.
Independent characterisation
Ling Yui is a sub-scale, single-market, single-segment cyclical contractor whose fortunes track Hong Kong private-sector land sales and foundation starts with a lag of 6–18 months. Gross margins have swung from 22.8% (FY2017) to –2.8% (FY2023) and back to 14.4% (FY2025) before falling again to 7.6% (FY2026), illustrating very limited pricing power. Since April 2026 the listed company's strategic identity is in flux: its new controller is a PRC genomics group, its name now references "AI" and "Life", and two genomics/AI scientists joined the board. Investors should therefore treat the construction business as the current earnings base and the potential injection or development of life-sciences activities as an unconfirmed option.
Strategy
Stated strategy themes (FY2026 Annual Report, paraphrased)
-
Prudent project selection and credit control: Focus on customers with proven records of timely settlement, accepting lower volume.
-
Cost control and prudent financial management amid a slow private property market and high interest rates.
-
Upgrade qualifications and financial resources to tender as a main contractor in the private sector.
-
Invest in manpower and information systems to improve capacity and efficiency.
-
Broaden the client base toward the public foundation sector via a dedicated project team targeting prominent clients with sizeable pipelines.
-
Leverage listed status to enhance reputation in the sector.
Strategic initiatives in the last 24 months
| Date | Initiative | Detail | Status |
|---|---|---|---|
| FY2026 | Credit-tightening programme | Selective customer engagement post-ECL charge | Ongoing |
| FY2026 | Public-sector business development team | Targeting large clients in public foundation works | Ongoing; no wins disclosed |
| 26 Jun 2025 | Workforce Diversity Policy | Group-wide inclusive workplace commitments | Adopted |
| 28 Aug 2025 | New M&A adopted | Hybrid/electronic meetings, treasury shares, paperless | Effective |
| 9 Apr 2026 | Change of control to HaploX vehicle | 70.02% acquired at HK$0.2375/share | Completed |
| 18 Jun 2026 | Rebrand to "AiLife International Group" | New English/Chinese names, stock short name from 4 Aug 2026 | Effective |
| FY2026 | Climate targets vs FY2022 base year | GHG intensity reduction targets (gross, no offsets, not SBTi-validated) | Ongoing |
Medium-term financial targets / guidance
None. The company provides no numerical revenue, margin or return targets. Management's qualitative outlook is that conditions "will remain challenging" with intense pricing competition.
Post-takeover strategic direction (analyst assessment)
The appointment of HaploX's founders, the "AiLife" name and the controller's background in genomics, liquid biopsy and bioinformatics strongly suggest the new controller intends to use the listed shell to develop or inject AI-enabled life-sciences or health businesses. The FY2026 report, however, states that there were no plans for material investments or capital assets as at 31 March 2026, and no acquisition, disposal of the construction business, or very substantial acquisition has been announced as of 11 October 2026. Any reverse-takeover-like injection would be subject to HKEX's stringent new-listing-equivalent rules (Chapter 14 RTO provisions), a material gating factor.
Products & Services
All offerings fall within the single foundation-engineering segment. No pricing schedules are published; work is priced by competitive tender per project.
Flagship projects: Named projects on hand, contract values and order backlog for FY2026 were not publicly disclosed in the sources reviewed (the annual report MD&A excerpt reviewed did not list them).
Life-sciences / AI offerings: None currently.
Product Portfolio
| Service line | Description | Key capabilities / specifications | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|---|
Excavation and lateral support (ELS) | Excavation of basements/pits with temporary support (sheet piles, struts, walings) to retain soil and protect adjacent structures | Sheet piling, large-scale excavation; experience cited in chairman's bio | Main contractors and developers of private projects | Core since 2000 | Lump-sum or re-measurement tender |
Pile construction | Installation of piles to transfer building loads to bearing strata | Aggregator profile cites large diameter bored piles, driven H-piles, pre-bored socket H-piles and mini-piles | Main contractors / developers | Core since 2000s | Tender |
Pile cap works | Construction of reinforced-concrete caps linking pile groups to superstructure | Formwork, rebar, concreting | Main contractors | Core | Tender |
Site formation | Earthworks, slope and level formation to prepare sites for construction | Earth-moving fleet | Developers / main contractors | Core | Tender |
Road and drainage works | Ancillary civil works associated with foundation projects | Small-scale civil works | Same | Ancillary | Tender / variation orders |
Machinery rental | Rental of owned machinery to third parties (recognised as other income) | Excavators and construction equipment | Other contractors | Recognised in FY2026 | Rental rate |
Sale of waste material | Sale of scrap/waste from sites (other income) | — | Recyclers | Recognised in FY2026 | Spot |
Financial Narrative
Basis: Audited consolidated statements, fiscal years ended 31 March. Figures from company filings unless flagged. "Agg." = aggregator-derived (TipRanks/ROIC.ai/Stoxray) and should be checked against the full annual report before reliance. Empty cells = not publicly disclosed in the sources reviewed.
Income statement
Notes: Direct costs for FY2022–FY2024 are derived as revenue minus gross profit. FY2026 D&A is ROIC.ai's rounded figure. FY2026 implied finance costs and other items (~HK$2.2M) cannot be separated from the extract reviewed.
Longer revenue history (context)
Sources: FY2018, FY2019, FY2022, FY2023, FY2025, FY2026 results; FY2017 gross profit derived from the 22.8% margin cited in FY2018 results; FY2017 profit derived from the 45.7% decline cited; FY2020 revenue per TipRanks.
Revenue CAGR: FY2022→FY2026 (4 years): approximately –15.0% p.a.; FY2021→FY2026 (5 years): approximately –5.7% p.a.; FY2017→FY2026 (9 years): approximately –2.2% p.a. (computed).
Balance sheet
Notes: Equity FY2022–FY2024 per ROIC.ai (rounded). Goodwill/intangibles inferred as nil because ROIC.ai tangible book value equals book value in every year. "Total debt" as defined by the company in the gearing calculation is substantially larger than bank borrowings (it likely includes lease liabilities, other loans and/or amounts due to related parties — the composition was not itemised in the extract reviewed).
Cash flow
ROIC.ai's rounded FCF per share implies roughly +HK$16M (FY2022), +HK$32M (FY2024) and –HK$16M (FY2025), each with ±HK$4M rounding error; TipRanks characterises recent operating and free cash flow as negative. The FY2026 report confirms no equity fund raising and no capital commitments.
Ratios
ROA, current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle cannot be calculated reliably without total assets, current liabilities, finance cost and receivable-day data — not publicly disclosed in sources reviewed. Net debt/EBITDA is in any case not meaningful in FY2025–FY2026 given negative or near-zero EBITDA.
Commentary on trends and drivers
Revenue. The Group's top line is lumpy and has been in structural decline since the FY2020 peak (HK$452.6M). FY2023's 30.6% drop reflected project delays and pandemic disruption; FY2024 fell a further 18.8% as Hong Kong's private development pipeline shrank under elevated HIBOR-linked borrowing costs. FY2025 recovered 10.5% to HK$214.5M, but management deliberately sacrificed volume in FY2026 (–16.4%) by restricting work to customers with sound payment records — a credit-control response to the FY2025 ECL hit. In other words, FY2026's revenue decline is partly self-imposed, an important nuance for anyone modelling recovery.
Gross margin. Margins have oscillated between –2.8% and 22.8% over a decade. The FY2023 gross loss reflected cost overruns and delays; FY2024–FY2025 margins of ~14–15% were the best since FY2018, but FY2026 margins halved to 7.6% because the Group accepted lower tender prices to keep its fleet and crews utilised. Management explicitly expects continued fierce price competition in the private foundation segment as rivals chase volume.
Operating costs. Administrative expenses are sticky at ~HK$27–28M, so the business needs roughly HK$200M+ of revenue at mid-teens gross margins just to break even at the operating line. FY2026 savings came from lower legal and professional fees (–HK$0.8M), lease depreciation (–HK$0.4M) and staff costs (–HK$0.3M).
Credit losses. The HK$22.2M ECL provision in FY2025 (≈10% of revenue) was the single largest swing factor and reveals the Group's exposure to counterparty stress among Hong Kong main contractors and developers.
Balance sheet. Equity has nearly halved in four years (HK$107M → HK$45.5M) through cumulative losses of ~HK$61M from FY2023 to FY2026. Positively, the Group repaid most bank borrowings (HK$25.0M → HK$2.3M) and reduced company-defined total debt from HK$75.0M to HK$41.3M, cutting gearing from 131.8% to 90.8%. Cash, however, fell to just HK$6.4M, which leaves little buffer for a business with large contract-asset balances.
Inflection. The investment case has inflected not on operations but on ownership: the HK$133M paid by Hapbiotech (HK$0.2375/share) was roughly 2.9x book value at the time, and the current market price (~HK$0.56) implies ~9.8x FY2026 book — a valuation that cannot be justified by the construction business alone.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Foundation engineering services revenue (HKD Mn) | 194.0 | 214.5 | 179.3 |
Segment gross profit (HKD Mn) | 28.6 | 31.0 | 13.6 |
Segment gross margin (%) | 14.8 | 14.4 | 7.6 |
YoY revenue growth (%) | -18.8 | 10.5 | -16.4 |
% of total revenue | 100 | 100 | 100 |
Group Entities
| Entity | Role | Source |
|---|---|---|
AiLife International Group Limited (Cayman) | Listed holding company | FY2026 AR |
Smart Sage (BVI, intermediate holding) | Holds Ming Lee Engineering (reorganisation 2017) | FY2019 results |
Southern Sun (BVI, intermediate holding) | Holds Ming Lee Foundation (reorganisation 2017) | FY2019 results |
Ming Lee Foundation Company Limited (HK) | Principal operating subsidiary; foundation works | FY2026 AR; prospectus |
Ming Lee Engineering Company Limited (HK) | Operating subsidiary; registered in Foundation category | FY2026 AR |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 344.3 | 239.0 | 194.0 | 214.5 | 179.3 |
Revenue growth (%) | 42.9 | -30.6 | -18.8 | 10.5 | -16.4 |
Direct costs (HKD Mn) | 319.5 | 245.6 | 165.4 | 183.5 | 165.7 |
Gross profit (HKD Mn) | 24.8 | -6.6 | 28.6 | 31.0 | 13.6 |
Gross margin (%) | 7.2 | -2.8 | 14.8 | 14.4 | 7.6 |
Other income and net gains (HKD Mn) | — | — | — | 0.7 | 3.8 |
Administrative expenses (HKD Mn) | — | — | — | 28.3 | 26.6 |
ECL impairment on receivables and contract assets (HKD Mn) | — | — | — | 22.2 | — |
Operating income, agg. (HKD Mn) | 2.05 | -33.98 | 0.98 | -19.09 | -11.35 |
Operating margin, agg. (%) | 0.6 | -14.2 | 0.5 | -8.9 | -6.3 |
Depreciation and amortisation, agg. (HKD Mn) | 12.05 | 9.83 | 12.27 | 12.86 | 11 |
EBITDA, agg. (HKD Mn) | 14.10 | -21.21 | 14.68 | -5.96 | — |
EBITDA margin, agg. (%) | 4.1 | -8.9 | 7.6 | -2.8 | — |
Pre-tax income, agg. (HKD Mn) | 3.08 | -32.72 | 0.66 | -20.55 | — |
Net income attributable (HKD Mn) | 2.24 | -30.04 | 0.66 | -20.55 | -11.4 |
Net margin (%) | 0.65 | -12.57 | 0.34 | -9.58 | -6.36 |
Basic EPS (HK cents) | 0.28 | -3.75 | 0.08 | -2.57 | -1.43 |
Diluted EPS (HK cents) | 0.28 | -3.75 | 0.08 | -2.57 | -1.43 |
Dividend per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (HKD Mn) | 219.3 | 331.1 | 289.2 | 452.6 | 241.0 | 344.3 | 239.0 | 194.0 | 214.5 | 179.3 |
Gross profit (HKD Mn) | 50.0 | 53.0 | 0.9 | — | 19.0 | 24.8 | -6.6 | 28.6 | 31.0 | 13.6 |
Net income attributable (HKD Mn) | 28.0 | 15.2 | -20.5 | — | -0.55 | 2.24 | -30.04 | 0.66 | -20.55 | -11.4 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total equity attributable (HKD Mn) | 107 | 77 | 77 | 56.9 | 45.5 |
Bank balances and cash (HKD Mn) | — | — | — | 14.7 | 6.4 |
Bank borrowings (HKD Mn) | — | — | — | 25.0 | 2.3 |
Total debt, company definition (HKD Mn) | — | — | — | 75.0 | 41.3 |
Net debt, company definition (HKD Mn) | — | — | — | 60.3 | 34.9 |
Gearing ratio, total debt / equity (%) | — | — | — | 131.8 | 90.8 |
Short-term debt, agg. Stoxray (HKD Mn) | — | 27.7 | 26.2 | — | — |
Long-term debt, agg. Stoxray (HKD Mn) | — | 3.3 | 13.2 | — | — |
Net debt, agg. Stoxray (HKD Mn) | — | 18.4 | 9.6 | — | — |
Working capital, agg. (HKD Mn) | 59 | 36 | 38 | 28 | 23 |
Goodwill and intangibles (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Pledged machinery NBV (HKD Mn) | — | — | — | 11.9 | 9.0 |
Pledged life-insurance policy (HKD Mn) | — | — | — | 4.2 | 4.2 |
Book value per share (HKD) | 0.13 | 0.10 | 0.10 | 0.07 | 0.06 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Free cash flow per share, agg. (HKD) | 0.02 | — | 0.04 | -0.02 | — |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Equity fund raising (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) and Income Statement
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, agg. (%) | 2.12 | -32.72 | 0.85 | -30.59 | -22.27 |
ROIC, agg. (%) | 2.27 | — | 1.03 | — | — |
Debt / equity, company gearing (%) | — | — | — | 131.8 | 90.8 |
Revenue per employee (HKD Mn) | — | — | 2.90 | 2.79 | 2.42 |
Staff cost / revenue (%) | — | — | — | 17.8 | 19.9 |
Admin expense / revenue (%) | — | — | — | 13.2 | 14.8 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hong Kong revenue (HKD Mn) | 194.0 | 214.5 | 179.3 |
Hong Kong growth (%) | -18.8 | 10.5 | -16.4 |
Mainland China revenue (HKD Mn) | 0 | 0 | 0 |
Rest of world revenue (HKD Mn) | 0 | 0 | 0 |
Valuation Snapshot
| Metric | Value | Source / basis |
|---|---|---|
Share price (≈11 Oct 2026) | HK$0.56 | ROIC.ai |
Market capitalisation | ~HK$448M | 800M shares × HK$0.56 |
Earlier 2026 aggregator quote | HK$0.81 (~HK$648M) | ROIC.ai (earlier snapshot) |
Last close before Apr 2026 suspension | HK$0.360 | Gelonghui |
Offer price (Apr–May 2026) | HK$0.2375 | FY2026 AR |
Apr 2023 block price | HK$0.145 | Announcement |
IPO indicative range | HK$0.45–0.55 | — |
Price ~Apr 2025 (aggregator) | ~HK$0.05 (market cap ~US$5M) | Stoxray |
P/E (FY2026) | Not meaningful (loss) | — |
P/B (FY2026 equity HK$45.5M) | ~9.8x | Computed |
EV (mkt cap + company-defined debt HK$41.3M – cash HK$6.4M) | ~HK$483M | Computed |
EV/Sales (FY2026) | ~2.7x | Computed |
Dividend yield | 0% | No dividends since listing per available data |
Capital Markets
| Metric | 1-Year | 3-Year | 5-Year |
|---|---|---|---|
Total return (%) | 302.88 | 330.77 | 278.38 |
Capital Markets (Annual)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Final dividend per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Analyst Conclusions
Management guidance
No quantitative guidance. Management expects the industry environment to remain challenging, with a slow private property market, persistently high interest rates, rising construction costs and fierce price competition. It will maintain prudent project selection and cost control, seek additional qualifications, strengthen financial resources, invest in manpower and IT, and pursue public-sector foundation opportunities (FY2026 AR).
Consensus
No consensus estimates exist.
Bull case
-
Platform optionality: A controller that paid HK$133M in cash and installed its two founders as executive directors likely intends to build or inject a meaningful AI/life-sciences business; HaploX's footprint (CLIA/CAP lab, GMP factory, Illumina partnership, ~700 institutional customers) could transform the listed entity's scale and growth profile.
-
Self-help in construction: FY2026's revenue decline was partly deliberate credit tightening; with debt largely repaid (bank borrowings HK$2.3M) and admin costs already trimmed, a modest volume recovery at FY2024–FY2025 margins (~14–15%) could restore break-even.
-
Cyclical recovery: Any easing of Hong Kong interest rates and a pickup in private land sales, combined with access to public works, could lift foundation demand from cyclical lows.
Bear case
-
Valuation detached from fundamentals: At ~9.8x book and ~2.7x EV/Sales for a loss-making contractor, the share price discounts a pivot that has not been announced and may face HKEX reverse-takeover scrutiny.
-
Deteriorating core business: Revenue has fallen ~15% p.a. over four years, gross margin halved to 7.6% in FY2026, cash is only HK$6.4M and equity has fallen ~58% since FY2022.
-
Minority-holder risk: Any asset injection from the controller would be a connected transaction priced by the controller; dilution or unfavourable terms are possible, and the offer's HK$0.2375 price anchors what the controller deemed fair value only months ago.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | Why it matters |
|---|---|---|
| Nov 2026 | Interim results for 6M to 30 Sep 2026 | First results under new control; check revenue run-rate, margins, cash, ECL |
| Any time | Announcements of acquisitions, disposals, connected transactions or VSAs | Clarifies the AiLife strategy; RTO classification risk |
| Any time | Placing of new shares or convertible issues | Funding for pivot; dilution |
| Ongoing | Board/management changes (e.g., new CEO from HaploX side, departure of construction team) | Signal on future of construction business |
| Dec 2026 | Three INEDs reach nine-year tenure | Independence assessment / board refresh |
| 2,027 | HK interest-rate path and private land sales | Core market demand |
| Mid-2027 | FY2027 annual results (expected ~June 2027) | Full-year view of new strategy |
Analyst verdict
AiLife International Group is two stories wrapped in one ticker. The first is a small, long-established Hong Kong foundation contractor — formerly Ling Yui — that has been shrinking and mostly unprofitable since FY2020. Its FY2026 numbers (revenue HK$179.3 million, gross margin 7.6%, net loss HK$11.4 million, cash HK$6.4 million, equity HK$45.5 million) describe a business that is managing decline sensibly — repaying borrowings, tightening credit, trimming overhead — but that lacks scale, pricing power or a visible catalyst for recovery while Hong Kong's private development market remains depressed. On a standalone basis, it would justify a valuation at or below book value, which is roughly HK$0.06 per share.
The second story is the April 2026 change of control. Hapbiotech, a vehicle of Shenzhen genomics group HaploX, paid HK$133 million for 70% of the company, renamed it "AiLife" and installed HaploX's two scientist-founders on the board. The market has responded by valuing the equity at around HK$448 million, nearly ten times book and more than double the HK$0.2375 offer price. That premium is a bet on a future, as-yet-unannounced transformation into an AI-enabled life-sciences platform.
Our assessment is that the construction business is a melting ice cube with limited downside protection from the balance sheet, while the pivot remains plausible but unproven and subject to significant regulatory, valuation and connected-party risk. The equity is therefore best characterised as a speculative special situation rather than an investment underpinned by fundamentals. Investors should demand concrete disclosure — the nature, valuation and funding of any assets to be injected, how minority interests are protected, and the fate of the foundation business — before treating current prices as anything other than option value. Until such disclosure, risk-reward appears skewed to the downside for fundamentals-driven holders.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age | Background / prior roles | Education |
|---|---|---|---|---|---|
Ling Chi Fai | Executive Director, Chairman; chair of Nomination Committee; member of Remuneration Committee | ED 1 Sep 2022 (with Group since 2000) | 63 | ~46 years in construction; Hang Fai Engineering (1980–97); Ming Lee Engineering project manager (1997); formerly Group GM/project manager; oversees site operations and tendering | — |
Leung Cheuk Ho | Executive Director, CEO | 29 Sep 2023 | 35 | 12+ years civil engineering; Ming Lee Foundation since 2016 (project manager, engineer, director); Rich Team Management (2011–16) | BSc Civil Engineering, Leeds Beckett University (2022); Professional Diploma, HK College of Technology (2020) |
Dr. Xu Mingyan | Executive Director | 11 May 2026 | 43 | Co-founded HaploX Investment Holding (Sept 2014); executive director there since Feb 2023; previously scientist at Cambrian Genomics (2013–14) | BSc Chemistry, Nanchang University; MSc Inorganic Chemistry, Beijing Normal University; PhD Biomedical Science, University of New Mexico |
Dr. Chen Shifu | Executive Director | 11 May 2026 | 41 | Co-founded HaploX (Sept 2014); responsible for product R&D and diagnostics development; formerly CUDA technical consultant and senior software engineer at NVIDIA Semiconductor (Shenzhen) (2010–14) | BSc Mathematics, Nanchang University; MSc Computer Software, ICT-CAS; PhD Pattern Recognition, Shenzhen Institute of Advanced Technology (CAS) |
Ling Yuk Tong (Tommy) | Non-executive Director; Nomination Committee member | 1 Nov 2024 | 38 | IT infrastructure specialist; iCON Business System (2013–15); assistant manager, TÜV Rheinland Hong Kong (since 2015); son of the Chairman | BSc Computing, Southampton Solent; MSc Computer Science, CityU HK; HND Civil Engineering (2021) |
Chong Kam Fung | INED; chair of Remuneration Committee | 4 Dec 2017 | 46 | HKICPA, FCCA; PwC (2006–13, senior manager); company secretary of Ahsay Backup Software (8290) | BA Accountancy, PolyU |
Ho Chun Chung Patrick | INED; chair of Audit Committee | 4 Dec 2017 | 62 | HKICPA, FCCA; PwC (1987–91); financial controller Gold Peak and Chen Hsong; INED of A & S Group (1737) and Realord Group (1196) | Prof. Diploma Accountancy, HK Polytechnic; MSc Finance, CityU HK |
Shi Wai Lim William | INED | 4 Dec 2017 | 48 | 28+ years construction; Chartered Building Engineer; director of Unibright Construction; former ED of GoldFinance Holdings (1462, delisted 2021) | Multiple professional qualifications |
Yau Suk Man | INED | 1 Nov 2024 | 48 | 26+ years in construction cost control; Gammon Skanska, Wheelock, COLI, Chun Wo, Fosun Property, Top Spring, Easyknit; contracts manager at Hip Shing Hong since 2023 | BSc Quantity Surveying, CityU HK; two MSc degrees, PolyU; MRICS |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Age | Notes |
|---|---|---|---|
Wong Chi Wai (Karl) | Chief Financial Officer (since 1 Jan 2018) | 40 | Ex-HLB Hodgson Impey Cheng (2011–15) — the Group's current audit firm; Coface Greater China (2015–16) |
Tsang Kwok Ping | Construction Manager | 54 | ~36 years in construction; with Group since 2000 |
Lo Hin Chi | Director of Ming Lee Engineering; authorised signatory (Foundation) | 35 | Chartered Civil Engineer; ex-Paul Y. Management and China Overseas |
Ng Hoi Ying | Company Secretary (outsourced) | 39 | HKICPA; ex-Deloitte; secretary to seven HK-listed companies |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Sep 2022 | Ling Chi Fai appointed ED and Chairman | Founder-operator returns to board leadership |
29 Sep 2023 | CEO Chan Siu Hung resigns (personal commitments); Leung Cheuk Ho appointed ED/CEO | Generational transition to an internal engineer |
1 Nov 2024 | Ling Yuk Tong (NED) and Yau Suk Man (INED) appointed | Follows Reach Goal offer in 2024 |
11 May 2026 | Dr. Xu Mingyan and Dr. Chen Shifu appointed EDs | Nominees of new controller Hapbiotech/HaploX |
Major Shareholders
| Holder | Shares | % of issued | Source |
|---|---|---|---|
Hapbiotech Investment Holding Limited (HaploX) | 560,140,000 + 90,000 offer acceptances | ~70.03 | FY2026 AR |
Public / other shareholders | ~239,770,000 | ~29.97 | Derived |
Total | 800,000,000 | 100 | FY2026 AR |
Competitive Landscape
Key Competitors
| Competitor | Listing | Segment overlap | Relative positioning |
|---|---|---|---|
Chinney Kin Wing (Chinney Alliance Group) | HKEX 0385 (parent) | Piling and foundation | Large, long-established foundation specialist with public-works track record |
Build King Holdings | HKEX 0240 | Civil engineering, foundation | Much larger, public-infrastructure oriented |
Asia Allied Infrastructure (Chun Wo) | HKEX 0711 | Civil, foundation, building | Diversified contractor |
Shun Wo Group Holdings | HKEX 1591 | Foundation works | Small-cap peer |
Royal Deluxe Holdings | HKEX 3789 | Foundation/ELS and machinery | Small-cap peer |
Wan Kei Group Holdings | HKEX 1718 | Foundation works | Small-cap peer |
Sang Hing Holdings | HKEX 1472 | Site formation and civil works | Small-cap peer |
Boill Healthcare Holdings (formerly Ngai Shun Holdings) | HKEX 1246 | Piling (historical) | Former piling peer that pivoted to healthcare — a precedent for Ling Yui's own possible pivot |
Gammon Construction | Private (JV) | Foundation, civil, building | Tier-1 contractor and potential customer/competitor |
Bachy Soletanche Group | Private | Specialist geotechnical/foundation | International specialist |
Competitor Detail
| Metric | Ling Yui / AiLife (FY2026) |
|---|---|
Revenue (HKD Mn) | 179.3 |
Revenue growth (%) | -16.4 |
Gross margin (%) | 7.6 |
Net margin (%) | -6.4 |
R&D intensity (%) | 0 |



